Ironwood Pharmaceuticals, Inc.

WHO'M
ai
Digital Profiler. Einfach den AI-Button klicken
CUSIP

46333X108
SEDOL

B3MZ6K5
CIK

0001446847

www.ironwoodpharma.com
LEI:
FIGI: BBG000GBZ3J2
IRWD

Ironwood Pharmaceuticals, Inc.
GICS: - · Sektor: Healthcare · Sub-Sektor: Drug Manufacturers—Specialty & Generic
AI
PROFILER
NAME
Ironwood Pharmaceuticals, Inc.
ISIN
US46333X1081
TICKER
IRWD
MIC
XNAS
REUTERS
IRWD.OQ
BLOOMBERG
IRWD US
GIF DE 728x90
FÜR INVESTOREN
FÜR TRADER
Börsenhandel Warrants
Der X-News Explorer ist die ultimative Informationsquelle für börsenaffine Anleger, die sich schnell und komfortabel einen Überblick über die aktuelle Nachrichtenlage eines börsennotierten Unternehmens verschaffen möchten. Ihnen stehen hier verschiedene Newswire-Services zur Verfügung. Wird ein News-Alert angezeigt, liegen Unternehmensnachrichten vor, die Sie möglicherweise interessieren könnten. Dieser Service wird Ihnen von BusinessWire bereitgestellt.
Di., 26.11.2024       Ironwood Pharmaceuticals
US46333X1081

Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced that management will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on Wednesday, December 4, 2024 at 12:30 p.m. ET at the Lotte New York Palace. A live webcast of Ironwood’s fireside chat will be accessible through the Investors section of the com...
Ironwood Pharmaceuticals
Mi., 13.11.2024       Ironwood Pharmaceuticals
US46333X1081

Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced that Sravan Emany, Chief Operating Officer and Chief Financial Officer, will participate in a fireside chat at the Jefferies London Healthcare Conference on Wednesday, November 20, 2024 at 7:30 a.m. GT at the Waldorf Hilton in London. A live webcast of Ironwood’s fireside chat will be ...
Ironwood Pharmaceuticals
Do., 07.11.2024       Ironwood Pharmaceuticals
US46333X1081

Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, today reported its third quarter 2024 results and recent business performance. “LINZESS continued to deliver robust prescription demand growth in the third quarter,” said Tom McCourt, chief executive officer of Ironwood Pharmaceuticals. “LINZESS extended units and new...
Ironwood Pharmaceuticals
Mo., 28.10.2024       Ironwood Pharmaceuticals
US46333X1081

Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, will present new findings at the American College of Gastroenterology (ACG) 2024 Annual Scientific Meeting and Postgraduate Course from subgroup analyses of the primary endpoint of the pivotal Phase III clinical trial, STARS, evaluating the treatment effect of apraglut...
Ironwood Pharmaceuticals
Do., 24.10.2024       Ironwood Pharmaceuticals
US46333X1081

Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced it will host its third quarter 2024 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, November 7, 2024. Individuals interested in participating in the call should dial (888) 596-4144 (U.S. and Canada) or (646) 968-2525 (international) using conference ID...
Ironwood Pharmaceuticals
Do., 29.08.2024       Ironwood Pharmaceuticals
US46333X1081

Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) will participate in a fireside chat at the 2024 Wells Fargo Healthcare Conference on Thursday, September 5, 2024 at 2:15 p.m. ET at the Encore Boston Harbor. A live webcast of Ironwood’s fireside chat will be accessible through the Investors section of the company’s website at www.ironwoodpharma.com....
Ironwood Pharmaceuticals
We are different
OPEN FINANCIAL
DATA & KNOWLEDGE HUB
We make the difference
Informationen zu Product Placements

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S